Log in to search using one of your social media accounts:

 

Iron overload in hematological disorders.

Iron overload in hematological disorders. Presse Med. 2017 Nov 22;: Authors: Fibach E, Rachmilewitz EA Abstract While most common symptom of impairment of iron homeostasis is iron deficiency anemia, some hematological disorders are associated with iron overload (IO). These disorders are related mainly to chronic severe hemolytic anemia, where red blood cells (RBC) or their precursors are destroyed prematurely (hemolyzed), leading to anemia that cannot be compensated by increased production of new RBC. In such cases, IO is mainly due to repeated RBC transfusions and/or increased uptake of iron in the gastrointestinal tract. Normally, iron is present in the plasma and in the cells bound to compounds that render it redox inactive. Iron overload leaves a fraction of the iron free (labile iron pool) and redox active, leading to the generation of excess free radicals such as the reactive oxygen species. This condition upsets the cellular redox balance between oxidants and antioxidants, leading to oxidative stress. The free radicals bind to various cellular components, thereby becoming toxic to vital organs. Oxidative stress may also affect blood cells, such as RBC, platelets and neutrophils, exacerbating the anemia, and causing recurrent infections and thrombotic events, respectively. The toxic effect of IO can be decreased by treating the patients with iron chelators that enter cells, bind free iron and remove it from the body through the urine and feces. Iro...
Source: Presse Medicale - Category: General Medicine Authors: Tags: Presse Med Source Type: research

Related Links:

We report the extraordinary case of a patient with MDS who developed T‐LGLL, and subsequently the MDS progressed to CMML. The patient then developed diffuse arthropod bite‐like papules and intractable pruritus.
Source: Clinical And Experimental Dermatology - Category: Dermatology Authors: Tags: Concise Report Source Type: research
Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Blasts Under 10 Percent of Bone Marrow Nucleated Cells;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive ;   Cytogenetic Abnormality;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Pancytopenia;   Refractory Anemia Interventions: &nb...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy that may deserve specific management. Defined by a persistent peripheral blood monocytosis ≥1 x 109/L and monocytes accounting for ≥10% of the white blood cells, this aging-associated disease combines cell proliferation as a consequence of myeloid progenitor hypersensitivity to granulocyte-macrophage colony-stimulating factor with myeloid cell dysplasia and ineffective hematopoiesis. The only curative option for CMML remains allogeneic stem cell transplantation. When transplantation is excluded, CMML is stratified into myelodysplastic (white blood cell count
Source: Blood - Category: Hematology Authors: Tags: How I Treat, Free Research Articles, Myeloid Neoplasia, Clinical Trials and Observations Source Type: research
In this month's issue, Festuccia et  al. describe how patients with myelodysplastic syndrome (MDS) fare when undergoing allogeneic hematopoietic cell transplantation (HCT) after hypomethylating agent (HMA) treatment, focusing on a comparison of those in whom HMA failed with those who responded to HMA [1]. The authors describe 125 pat ients with MDS at their institution who underwent HCT after HMA therapy between 2004 and 2013, representing the full spectrum of MDS, from refractory cytopenia with multilineage dysplasia to chronic myelomonocytic leukemia to refractory anemia with excess blasts 2.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Conditions:   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic;   Anemia, Refractory, With Excess of Blasts Intervention:   Drug: IGF/MTX Sponsor:   IGF Oncology, LLC Not yet recruiting - verified May 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Anemia | Antidoxidants | Chronic Leukemia | Gastroenterology | General Medicine | Hematology | Iron | Leukemia | Myelodysplastic Syndrome | Toxicology